[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532384":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":71,"collaborators":73,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":26,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":26,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Bedaya Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Progestin primed ovarian stimulation group","EXPERIMENTAL","HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg\u002Fday was used to prevent premature LH surge during the FPS and LPS.\n\nIn subsequent cycle, frozen embryo transfer was done",[13],"Drug: Progestin primed ovarian stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"GnRH antagonist group","ACTIVE_COMPARATOR","HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.\n\nIn subsequent cycle, frozen embryo transfer was done",[19],"Drug: GnRH antagonist",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Progestin primed ovarian stimulation","HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg\u002Fday was used to prevent premature LH surge during the FPS and LPS.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"GnRH antagonist","HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.",[15],[32],{"name":33,"affiliation":34,"role":35},"Samar A Alhofy, M.D, Msc","Cairo University","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Usama M Fouda, Prof.","CONTACT","+201095401375","umfrfouda@yahoo.com",[43,59],{"facility":34,"status":44,"city":45,"state":46,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Cairo","Cairo Governorate","Egypt","EG",{"type":50,"coordinates":51},"Point",[52,53],31.24967,30.06263,{"lat":53,"lon":52},[56,58],{"name":57,"role":39,"phone":40,"phoneExt":26,"email":41},"Usama M Fouda, Prof",{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"facility":5,"status":60,"city":61,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"NOT_YET_RECRUITING","Giza",{"type":50,"coordinates":63},[64,65],31.20861,30.00944,{"lat":65,"lon":64},[68,70],{"name":69,"role":39,"phone":26,"phoneExt":26,"email":41},"Usama M. Fouda, Prof",{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"type":72,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[74],{"name":34,"class":6},"100532384","phase-2-dydrogesterone-versus-gnrh-antagonist-in-poor-responders-undergoing-double-ovarian-stimulation-100532384",false,"NCT06212102","Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation","Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial","Inclusion Criteria:\n\nPatients belonging to Poseidon group 4\n\nExclusion Criteria:\n\n* PCOS\n* Endometriosis\n* History of recurrent abortion","FEMALE","35 Years","44 Years",{"count":86,"type":87},120,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.",[93],"Infertility",[93,95,96,97],"IVF-ET","Poor ovarian responders","Double stimulation","2026-04-28",{"date":100,"type":101},"2026-05-04","ACTUAL",{"date":103,"type":101},"2024-05-08",{"date":105,"type":87},"2027-08-01",{"name":5,"class":6},2]